Unlocking the Secrets to a Sharper Mind and Healthier Cells
April 17, 2024 09:00 ET
|
Return Healthy
St. George, Utah, April 17, 2024 (GLOBE NEWSWIRE) -- In an era of rising health concerns, particularly those affecting cognitive functions, Return Healthy reveals its groundbreaking Cell...
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
March 14, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in...
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
February 22, 2024 07:00 ET
|
AC Immune SA
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to...
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
January 22, 2024 07:00 ET
|
AC Immune SA
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now...
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
January 03, 2024 08:10 ET
|
AC Immune SA
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and...
CeramicFlowers Supports Alzheimer’s Society This Christmas
December 27, 2023 08:59 ET
|
Ceramic Flowers
Kidlington, Oxford, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CeramicFlowers, a UK-based business that creates ceramic flowers for graves and memorial gardens, is proud to announce that it is supporting...
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
November 02, 2023 07:00 ET
|
AC Immune SA
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune...
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 05, 2023 07:00 ET
|
AC Immune SA
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage...
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat...